HomeCompareVBIO vs GBDC

VBIO vs GBDC: Dividend Comparison 2026

VBIO yields 512.82% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VBIO wins by $74698.60M in total portfolio value
10 years
VBIO
VBIO
● Live price
512.82%
Share price
$0.39
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$74719.37M
Annual income
$54,003,807,702.14
Full VBIO calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — VBIO vs GBDC

📍 VBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVBIOGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VBIO + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VBIO pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VBIO
Annual income on $10K today (after 15% tax)
$43,589.74/yr
After 10yr DRIP, annual income (after tax)
$45,903,236,546.82/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, VBIO beats the other by $45,889,305,672.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VBIO + GBDC for your $10,000?

VBIO: 50%GBDC: 50%
100% GBDC50/50100% VBIO
Portfolio after 10yr
$37370.07M
Annual income
$27,010,098,482.77/yr
Blended yield
72.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

VBIO
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VBIO buys
0
GBDC buys
0
No recent congressional trades found for VBIO or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVBIOGBDC
Forward yield512.82%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$74719.37M$20.78M
Annual income after 10y$54,003,807,702.14$16,389,263.41
Total dividends collected$72929.43M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: VBIO vs GBDC ($10,000, DRIP)

YearVBIO PortfolioVBIO Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$61,982$51,282.05$12,490$1,790.28+$49.5KVBIO
2$363,383$297,062.31$16,522$3,157.73+$346.9KVBIO
3$2,016,476$1,627,655.79$23,578$5,898.68+$1.99MVBIO
4$10,598,885$8,441,255.59$37,115$11,886.75+$10.56MVBIO
5$52,806,644$41,465,837.52$66,136$26,423.57+$52.74MVBIO
6$249,582,121$193,079,012.24$137,257$66,491.44+$249.44MVBIO
7$1,119,909,823$852,856,952.70$341,734$194,868.54+$1119.57MVBIO
8$4,774,834,551$3,576,531,040.71$1,050,788$685,133.02+$4773.78MVBIO
9$19,360,340,566$14,251,267,596.86$4,099,314$2,974,971.01+$19356.24MVBIO
10$74,719,372,108$54,003,807,702.14$20,775,530$16,389,263.41+$74698.60MVBIO

VBIO vs GBDC: Complete Analysis 2026

VBIOStock

Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of inflammatory disorders in the United States. The company is developing tetrahydrocannabinol glycoside (VBX-100), an oral cannabinoid prodrug for inflammatory bowel disease and irritable bowel syndromes. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. was founded in 2007 and is headquartered in Los Angeles, California.

Full VBIO Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this VBIO vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VBIO vs SCHDVBIO vs JEPIVBIO vs OVBIO vs KOVBIO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.